First AD

Second AD

Multiple Myeloma

Around the Practice

Previously recorded peer-to-peer panel discussions featuring authoritative insights, opinions, and perspectives on case presentations and audience engagement on important issues facing today's cancer care professionals.

Recent Advances in Multiple Myeloma: Insights from Experts at Levine Cancer Center, Duke University and UNC Lineberger Cancer Center

 is a virtual event featuring multidisciplinary experts in oncology discussing the latest developments in cancer care as they review patient cases. Every ATP event is unique, and we strive to deliver best-in-class awareness, so the oncology community can learn on-demand.

Dr Tuchman highlights exciting bispecific agents in investigation for the treatment of relapsed/refractory multiple myeloma.

Bispecifics in Development for the Treatment of R/R MM

Patient Profile: A 59-Year-Old Man with Transplant Eligible Newly-Diagnosed Multiple Myeloma (NDMM)

Available Induction Regimen Options for Patients with Transplant-Eligible NDMM

Recap: Recent Research in Multiple Myeloma

Evaluating MRD-Guided Therapy in Patients with NDMM

Assessing Response and Duration of Treatment in Transplant-Eligible NDMM

Patient Profiles: Transplant-Ineligible Newly-Diagnosed Multiple Myeloma

Selecting Frontline Treatment Regimens for Transplant-Ineligible MM

Data Updates in Transplant Ineligible NDMM

Measuring Treatment Response and Duration of Treatment in Transplant-Ineligible MM

Defining Frail Patients in Multiple Myeloma

Treatment Options for Patients with Relapsed Multiple Myeloma

Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM